

KING & SPALDING LLP  
1185 Avenue of the Americas  
New York, New York 10036-2601  
Telephone: (212) 556-2100  
Facsimile: (212) 556-2222  
Scott Davidson

*Special Counsel to the Debtors and Debtors in Possession*

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

**In re:**

**PURDUE PHARMA L.P., *et al.*,  
Debtors.<sup>1</sup>**

**Chapter 11**

**Case No. 19-23649 (RDD)  
(Jointly Administered)**

**SECOND MONTHLY FEE STATEMENT OF KING & SPALDING LLP  
FOR COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT  
OF EXPENSES INCURRED AS SPECIAL COUNSEL TO THE  
DEBTORS AND DEBTORS IN POSSESSION FOR THE PERIOD FROM  
OCTOBER 1, 2019 THROUGH OCTOBER 31, 2019**

|  |  |
|--|--|
| <b>Name of Applicant</b>   | King & Spalding LLP                                  |
| <b>Applicant's Role in Case</b>                                  | Special Counsel to Purdue Pharma L.P., <i>et al.</i> |
| <b>Date Order of Employment Signed</b>                           | November 25, 2019 [Docket No. 543]                   |
| <b>Period for Which Compensation and Reimbursement is Sought</b> | October 1, 2019 through October 31, 2019             |

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

| Summary of Total Fees and Expenses Requested  |                                       |
|---|---------------------------------------|
| Total Compensation Requested in this Statement  | \$466,797.08<br>(80% of \$583,496.35) |
| Total Reimbursement Requested in this Statement   | \$0                                   |
| Total Compensation and Reimbursement Requested in this Statement  | \$466,797.08                          |
| This is a(n): <input checked="" type="checkbox"/> Monthly Application <input type="checkbox"/> Interim Application <input type="checkbox"/> Final Application |                                       |

Pursuant to sections 327, 330, and 331 of chapter 11 of title 11 of the United States Code (the “**Bankruptcy Code**”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”), Rule 2016-1 of the Local Bankruptcy Rules for the United States Bankruptcy Court for the Southern District of New York (the “**Local Rules**”), the *Order Authorizing the Retention and Employment of King & Spalding LLP as Special Counsel for the Debtors Nunc Pro Tunc to the Petition Date*, dated November 25, 2019 [Docket No. 543] (the “**Retention Order**”), and the *Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals*, dated November 21, 2019 [Docket No. 529] (the “**Interim Compensation Order**”), King & Spalding LLP (“**K&S**”), special counsel to the above-captioned debtors and debtors in possession (collectively, the “**Debtors**”), submits this *Monthly Statement of Services Rendered and Expenses Incurred for the Period from October 1,*

2019 Through October 31, 2019 (this “**Fee Statement**”).<sup>2</sup> By this Fee Statement, and after taking into account certain voluntary discounts and reductions,<sup>3</sup> K&S seeks (i) compensation in the amount of \$466,797.08 which is equal to 80% of the total amount of reasonable compensation for actual, necessary legal services that K&S incurred in connection with such services during the Fee Period (*i.e.*, \$583,496.35) and (ii) payment of \$0 for the actual, necessary expenses that K&S incurred in connection with such services during the Fee Period.

**Itemization of Services Rendered and Disbursements Incurred**

1. Attached hereto as **Exhibit A** is a chart of the number of hours expended and fees incurred (on an aggregate basis) by K&S partners, counsel, associates, discovery counsel, privilege review attorneys, and paraprofessionals during the Fee Period with respect to each of the project categories K&S established in accordance with its internal billing procedures. As reflected in **Exhibit A**, K&S incurred \$583,496.35 in fees during the Fee Period. Pursuant to this Fee Statement, K&S seeks reimbursement for 80% of such fees, totaling \$466,797.08.

2. Attached hereto as **Exhibit B** is a chart of K&S professionals and paraprofessionals, including the standard hourly rate for each attorney and paraprofessional who rendered services to the Debtors in connection with these chapter 11 cases during the Fee Period and the title, hourly rate, aggregate hours worked and the amount of fees earned by each professional. The blended

---

<sup>2</sup> The period from October 1, 2019 through and including October 31, 2019 is referred to herein as the “**Fee Period**.”

<sup>3</sup> K&S agreed as a courtesy to the Debtors to bill at approximately 90% of its market hourly rates in effect when the services are rendered. Additionally, K&S agreed to offer additional discounts, on a sliding scale, on fees exceeding certain amounts.

hourly billing rate of attorneys for all services provided during the Fee Period is \$263.61.<sup>4</sup> The blended hourly billing rate of all paraprofessionals is \$198.88.<sup>5</sup>

3. Attached hereto as **Exhibit C** is a chart of expenses that K&S incurred or disbursed in the amount of \$0 in connection with providing professional services to the Debtors during the Fee Period. These expense amounts are intended to cover K&S's direct operating costs, which costs are not incorporated into K&S's hourly billing rates. Only the clients for whom the services are actually used are separately charged for such services. The effect of including such expenses as part of the hourly billing rates would unfairly impose additional cost upon clients who do not require extensive photocopying, delivery and other services.

4. Attached hereto as **Exhibit D** are the time records of K&S for the Fee Period organized by project category with a daily time log describing the time spent by each attorney and other professional during the Fee Period as well as an itemization of expenses.

#### **Notice**

5. K&S will provide notice of this Fee Statement in accordance with the Interim Compensation Order. K&S submits that no other or further notice be given.

*[Remainder of Page Intentionally Left Blank]*

---

<sup>4</sup> The blended hourly rate of \$263.61 for attorneys is derived by dividing the total fees for attorneys of \$578,305.71 by the total hours of 2,193.8.

<sup>5</sup> The blended hourly rate of \$198.88 for paraprofessionals is similarly derived by dividing the total fees for paraprofessionals of \$5,190.64 by the total hours of 26.1.

WHEREFORE, K&S, in connection with services rendered on behalf of the Debtors, respectfully requests (i) compensation in the amount of \$466,797.08, which is equal to 80% of the total amount of reasonable compensation for actual, necessary legal services that K&S incurred in connection with such services during the Fee Period (*i.e.*, \$583,496.35) and (ii) payment of \$0 for the actual, necessary expenses that K&S incurred in connection with such services during the Fee Period.

Dated: December 11, 2019  
New York, New York

**KING & SPALDING LLP**

/s/ Scott Davidson

Scott Davidson  
1185 Avenue of the Americas  
New York, New York 10036-2601  
Telephone: (212) 556-2100  
Facsimile: (212) 556-2222

*Special Counsel to the Debtors and Debtors in Possession*

**Exhibit A**

**Fees by Project Category**

| <b>Project Category</b>       | <b>Total Hours</b> | <b>Total Fees</b>   |
|-------------------------------|--------------------|---------------------|
| Analysis/Strategy             | 64.1               | \$60,283.80         |
|                               | 144.2              | \$51,816.58         |
| Document/File Management      | 92.2               | \$27,717.95         |
| Document Production (Defense) | 1,731.5            | \$344,387.90        |
| Other Case Assessment         | .4                 | \$79.55             |
| Other Discovery (Defense)     | 25.7               | \$5,111.07          |
| Retention and Fee Application | 161.8              | \$94,099.50         |
| <b>TOTALS</b>                 | <b>2,219.9</b>     | <b>\$583,496.35</b> |

**Exhibit B**

**Professional & Paraprofessional Fees<sup>6</sup>**

---

<sup>6</sup> The hourly billing rate and total compensation listed in Exhibit B for each timekeeper do not reflect either the 7.5% or 10% discount, as applicable, agreed to with the Debtors.



| <b>Name of Professional Individual</b> | <b>Position, Year Assumed Position, Prior Relevant Experience, years of Obtaining Relevant License to Practice</b> | <b>Hourly Billing Rate</b> | <b>Total Hours Billed</b> | <b>Total Compensation</b> |
|--|--|----------------------------|---------------------------|---------------------------|
| <b>Partners</b>                        |  |                            |                           |                           |
| Sarah R. Borders                       | Partner; joined K&S 1989; admitted to Georgia 1989   | \$1,135                    | 1.7                       | \$1,929.50                |
| Jeffrey S. Bucholtz                    | Partner; joined K&S 2009; admitted to Washington, D.C. 1996  | \$1,045                    | 67.4                      | \$70,433                  |
| Rose Jones                             | Partner; joined K&S 2003; admitted to Georgia 2002   | \$425                      | 93.4                      | \$39,695.00               |
| Seth Lundy                             | Partner; joined K&S 2008; admitted to Maryland 1996  | \$1,040                    | .5                        | \$520.00                  |
| <b>Counsel</b>                         |  |                            |                           |                           |
| Scott Davidson                         | Counsel; joined K&S 2009; admitted to New York 1996  | \$1,130                    | 5.9                       | \$6,667.00                |
| <b>Associates</b>                      |  |                            |                           |                           |
| Lindsey Henrikson                      | Associate; joined K&S 2019; admitted to Illinois 2015  | \$750                      | 12.8                      | \$9,600.00                |
| Matt Higgins                           | Associate; joined K&S 2019; admitted to Georgia 2019   | \$450                      | 8.5                       | \$3,825.00                |
| Jake Jumbeck                           | Associate; joined K&S 2019; admitted to Illinois 2017  | \$620                      | 18.0                      | \$11,160.00               |
| Christian Sae                          | Associate; joined K&S 2018; admitted to New York 2018  | \$695                      | 21.9                      | \$15,220.50               |
| Leia Shermohammed                      | Associate; joined K&S 2017; admitted to Georgia 2015   | \$585                      | 89.2                      | \$52,182.00               |
| <b>Discovery Counsel</b>               |  |                            |                           |                           |
| Nicole Bass                            | Discovery counsel; joined K&S 2010; admitted to Georgia 2010   | \$325                      | 141.3                     | \$45,922.50               |
| Katherine Webb                         | Discovery counsel; joined K&S 2014; admitted to Georgia 2014   | \$280                      | 0.6                       | \$168.00                  |
| <b>Privilege Review Attorneys</b>      |  |                            |                           |                           |
| Michael Douglas                        | Privilege review attorney; joined K&S 2003; admitted to Georgia 1999   | \$215                      | 16.0                      | \$3,440.00                |
| Frankie Evans                          | Privilege review attorney; joined K&S 2000; admitted to Georgia 1999   | \$215                      | 8.1                       | \$1,741.50                |

| <b>Name of Professional Individual</b> | <b>Position, Year Assumed Position, Prior Relevant Experience, years of Obtaining Relevant License to Practice</b> | <b>Hourly Billing Rate</b> | <b>Total Hours Billed</b> | <b>Total Compensation</b> |
|--|--|----------------------------|---------------------------|---------------------------|
| Antoine Grady                          | Privilege review attorney; joined K&S 2018; admitted to Washington, D.C. 2018                                      | \$215                      | 98.4                      | \$21,156.00               |
| Jay Haider                             | Privilege review attorney; joined K&S 2012; admitted to Georgia 2012   | \$215                      | 92.9                      | \$19,973.50               |
| Priya Kolli                            | Privilege review attorney; joined K&S 2014; admitted to Georgia 2014   | \$215                      | 55.8                      | \$11,997.00               |
| Lori Maryscuk                          | Privilege review attorney; joined K&S 2000; admitted to Georgia 1997   | \$215                      | 161.0                     | \$34,615.00               |
| Liz McGovern                           | Privilege review attorney; joined K&S 2014; admitted to Georgia 2014   | \$215                      | 85.7                      | \$18,425.50               |
| Chong Pak                              | Privilege review attorney; joined K&S 2015; admitted to Georgia 2012   | \$215                      | 144.7                     | \$31,110.50               |
| Alex Panos                             | Privilege review attorney; joined K&S 2002; admitted to Georgia 1997   | \$215                      | 3.1                       | \$666.50                  |
| Reilly Schreck                         | Privilege review attorney; joined K&S 2012; admitted to Georgia 2012   | \$215                      | 107.5                     | \$23,112.50               |
| Eric Smedley                           | Privilege review attorney; joined K&S 2000; admitted to Georgia 1999   | \$215                      | 22.5                      | \$4,837.50                |
| Sarah Tona                             | Privilege review attorney; joined K&S 2017; admitted to Georgia 2018   | \$215                      | 16.4                      | \$3,526.00                |
| Nikki Bradley                          | Privilege review attorney; joined K&S 2018; admitted to Georgia 2018   | \$215                      | 12.4                      | \$2,666.00                |
| Kyle Brahe                             | Privilege review attorney; joined K&S 2017; admitted to Georgia 2010   | \$215                      | 136.0                     | \$29,240.00               |
| Jeffrey Domozyk                        | Privilege review attorney; joined K&S 2018; admitted to Georgia 2018   | \$215                      | 119.5                     | \$25,692.50               |

| <b>Name of Professional Individual</b> | <b>Position, Year Assumed Position, Prior Relevant Experience, years of Obtaining Relevant License to Practice</b> | <b>Hourly Billing Rate</b> | <b>Total Hours Billed</b> | <b>Total Compensation</b> |
|--|--|----------------------------|---------------------------|---------------------------|
| Matthew Dyer                           | Privilege review attorney;<br>joined K&S 2018;<br>admitted to Georgia 2002   | \$215                      | 8.1                       | \$1,741.50                |
| Michael Hervey                         | Privilege review attorney;<br>joined K&S 2015;<br>admitted to Georgia 2016   | \$215                      | 2.3                       | \$494.50                  |
| Kimberlee Hillard                      | Privilege review attorney;<br>joined K&S 2018;<br>admitted to Georgia 2010   | \$215                      | 131.2                     | \$28,208.00               |
| Elizabeth Rankin                       | Privilege review attorney;<br>joined K&S 2019;<br>admitted to Georgia 1993   | \$215                      | 126.1                     | \$27,111.50               |
| Justin Saxon                           | Privilege review attorney;<br>joined K&S 2006;<br>admitted to Georgia 2005   | \$215                      | 140.5                     | \$30,207.50               |
| Nathaniel Sherman                      | Privilege review attorney;<br>joined K&S 2015;<br>admitted to Georgia 2014   | \$215                      | 89.0                      | \$19,135.00               |
| Joseph Sherman                         | Privilege review attorney;<br>joined K&S 2018;<br>admitted to Georgia 2017   | \$215                      | 85.0                      | \$18,275.00               |
| Hao Wang                               | Privilege review attorney;<br>joined K&S 2016;<br>admitted to Georgia 2017   | \$215                      | 70.4                      | \$15,136.00               |
| <b>Paraprofessionals</b>               |  |                            |                           |                           |
| Dan Handley                            | Senior Paralegal;<br>joined K&S 2003   | \$215                      | 26.1                      | \$5,611.50                |

**Exhibit C**

**Summary of Actual and Necessary Expenses**

| Expense Category | Total Expenses |
|------------------|----------------|
| <b>TOTAL</b>     | <b>\$0</b>     |

**Exhibit D**

**Detailed Time Records and Expenses**

# KING & SPALDING

FEDERAL I.D. 58-0520153

Remit To:  
King & Spalding LLP  
P.O. Box 116133  
Atlanta, GA 30368-6133

By Wire: SunTrust Bank  
ABA: 061 000 104  
SWIFT: SNTRUS3A  
USD Account: 88003 12475  
Account Name: King & Spalding

Purdue Pharma LP  
Sent Electronically

Invoice No. 10311310  
Invoice Date 12/09/19  
Client No. 08714  
Matter No. 158001

RE: DOJ Opioid Marketing Investigations  
Client Matter Reference: 20190002327

For questions, contact:  
Jeffrey Bucholtz (202) 626-2907

For Professional Services Rendered from October 1, 2019 through October 31, 2019:

|                              |           |                  |
|------------------------------|-----------|------------------|
| Fees                         | \$        | 66,982.00        |
| Less Agreed Discount (10.0%) |           | -6,698.20        |
| <b>Total this Invoice</b>    | <b>\$</b> | <b>60,283.80</b> |

*Payment is Due Upon Receipt*

08714 Purdue Pharma LP  
158001 DOJ Opioid Marketing Investigations  
12/09/19

Invoice No. 10311310  
Page 2

# **PROFESSIONAL SERVICES**

| Date     | Timekeeper | Task | Activity | Description   | Hours |
|----------|------------|------|----------|---|-------|
| 10/01/19 | J Bucholtz | L120 | A106     | Confer with M. Kesselman, J. Adams, W. Nordwind, P. Fitzgerald, J. Bragg, M. Florence, and team regarding DOJ issues (1.3); confer with M. Kesselman, J. Adams, P. Fitzgerald, M. White, T. Wells, and team regarding DOJ issues (0.7)  | 2.0   |
| 10/02/19 | J Bucholtz | L120 | A106     | Confer with J. Adams, P. Fitzgerald, and team regarding DOJ issues (1.1); confer with G. McCarthy, and team regarding bankruptcy court issues (0.3)   | 1.4   |
| 10/03/19 | J Bucholtz | L120 | A106     | Confer with M. Kesselman, Board, and team regarding bankruptcy court and DOJ issues (1.0); confer with M. Kesselman, P. Fitzgerald, and team regarding DOJ issues (1.3); confer with M. Kesselman, J. Adams, P. Fitzgerald, M. White, T. Wells, and team regarding DOJ issues (1.1)                 | 3.4   |
| 10/04/19 | J Bucholtz | L120 | A106     | Confer with M. Kesselman, M. Huebner, P. Fitzgerald, J. Bragg, and team regarding bankruptcy court and DOJ issues (1.6); confer with DOJ regarding next steps and brief M. Kesselman, P. Fitzgerald, J. Bragg, and team regarding same (1.8); review materials regarding potential DOJ issues (1.2) | 4.6   |
| 10/07/19 | J Bucholtz | L120 | A107     | Confer with P. Fitzgerald, J. Bragg, and team regarding DOJ issues  | 0.3   |
| 10/08/19 | J Bucholtz | L120 | A106     | Confer with M. Kesselman, J. Adams, P. Fitzgerald, J. Bragg, and team regarding DOJ issues (2.1); confer with DOJ regarding next steps (0.6); confer with M. Kesselman, P. Fitzgerald, J. Bragg, M. White, T. Wells, and team regarding DOJ issues (0.8)  | 3.5   |
| 10/09/19 | J Bucholtz | L120 | A107     | Confer with P. Fitzgerald and J. Bragg regarding DOJ issues (1.7); confer with M. Huebner, P. Fitzgerald, and team regarding bankruptcy court issues (0.3)  | 2.0   |
| 10/10/19 | J Bucholtz | L120 | A106     | Confer with M. Kesselman, J. Adams, P. Fitzgerald, J. Bragg, and team regarding DOJ issues (1.4); confer with M. Kesselman, J. Adams, P. Fitzgerald,  | 2.5   |



08714 Purdue Pharma LP  
158001 DOJ Opioid Marketing Investigations  
12/09/19

Invoice No. 10311310  
Page 3

| Date     | Timekeeper | Task | Activity | Description   | Hours |
|----------|------------|------|----------|---|-------|
|          |            |      |          | J. Bragg, M. White, T. Wells, and team regarding DOJ issues (1.1)   |       |
| 10/11/19 | J Bucholtz | L120 | A107     | Confer with DOJ regarding next steps and brief P. Fitzgerald, and team regarding same (1.8); confer with P. Fitzgerald, R Finzi, and team regarding DOJ issues (0.8); confer with M. Huebner, P. Fitzgerald, J. Bragg, and team regarding bankruptcy and DOJ issues (0.7)   | 3.3   |
| 10/12/19 | J Bucholtz | L120 | A106     | Confer with DOJ regarding next steps and brief M. Kesselman, J. Adams, P. Fitzgerald, M. Florence, and team regarding same (1.3); confer with M. Kesselman, J. Adams, P. Fitzgerald, M. White, T. Wells, and team regarding DOJ issues (1.6)  | 2.9   |
| 10/13/19 | J Bucholtz | L120 | A106     | Correspond with M. Kesselman, P. Fitzgerald, and team regarding DOJ issues (0.3); review materials regarding same (0.3)   | 0.6   |
| 10/14/19 | J Bucholtz | L120 | A104     | Review materials regarding MDL and DOJ issues   | 0.6   |
| 10/15/19 | J Bucholtz | L120 | A106     | Meet with M. Kesselman, J. Adams, W. Nordwind, P. Fitzgerald, J. Bragg, R. Stoll regarding DOJ issues (4.2); review materials regarding next steps with DOJ to prepare for meeting (0.8)  | 5.0   |
| 10/16/19 | J Bucholtz | L120 | A106     | Confer with DOJ regarding next steps and brief M. Kesselman, P. Fitzgerald, and J. Bragg regarding same (1.2); review materials regarding next steps with DOJ (0.6)   | 1.8   |
| 10/17/19 | J Bucholtz | L120 | A106     | Confer with S Lundy regarding DOJ resolution issues (0.4); confer with DOJ and team regarding next steps (0.5); confer with M. Kesselman, J. Adams, W. Nordwind, P. Fitzgerald, J. Bragg, and team regarding next steps with DOJ (1.1); review materials regarding next steps with DOJ (0.4); confer with Board, M. Kesselman, and team regarding DOJ and litigation issues (2.3) | 4.7   |
| 10/17/19 | S Lundy    | L120 | A105     | Confer with J. Bucholtz regarding DOJ resolution issues   | 0.5   |
| 10/18/19 | J Bucholtz | L120 | A106     | Confer with M. Kesselman, J. Adams,   | 2.3   |

08714 Purdue Pharma LP  
158001 DOJ Opioid Marketing Investigations  
12/09/19

Invoice No. 10311310  
Page 4

| Date     | Timekeeper | Task | Activity | Description   | Hours |
|----------|------------|------|----------|---|-------|
|          |            |      |          | P. Fitzgerald, and J. Bragg regarding DOJ issues (1.1); confer with M. Kesselman, P. Fitzgerald, M White, T Wells, and team regarding DOJ issues (0.8); edit materials regarding next steps with DOJ (0.4)                                      |       |
| 10/21/19 | J Bucholtz | L120 | A107     | Confer with DOJ and team regarding next steps (0.4); confer with P. Fitzgerald, J. Bragg, and team regarding call with DOJ (0.6)  | 1.0   |
| 10/22/19 | J Bucholtz | L120 | A106     | Confer with DOJ and team regarding next steps (0.6); confer with M. Kesselman, J. Adams, W. Nordwind, P. Fitzgerald, and team regarding DOJ issues (0.7); confer with M. Kesselman, P. Fitzgerald, M White, and team regarding DOJ issues (0.5) | 1.8   |
| 10/23/19 | J Bucholtz | L120 | A106     | Confer with DOJ and brief M. Kesselman and team regarding DOJ issues  | 1.0   |
| 10/24/19 | J Bucholtz | L120 | A107     | Confer with P. Fitzgerald and team regarding DOJ issues (0.9)   | 0.9   |
| 10/25/19 | J Bucholtz | L120 | A107     | Confer with P. Fitzgerald, J. Bragg, M. Florence, J. McClammy, and team regarding DOJ and bankruptcy court issues (0.8); review draft materials regarding DOJ issues (0.4)  | 1.2   |
| 10/27/19 | J Bucholtz | L120 | A104     | Confer with M. Kesselman, J. Adams, P. Fitzgerald, J. Bragg, M. Huebner, J. McClammy, and team regarding DOJ and bankruptcy court issues (1.8); review draft materials regarding DOJ and bankruptcy court issues (1.0)                          | 2.8   |
| 10/28/19 | J Bucholtz | L120 | A106     | Confer with M. Kesselman, J. Adams, W. Nordwind, P. Fitzgerald, J. Bragg, M. Huebner, and team regarding DOJ resolution issues (1.6); review and edit draft materials regarding DOJ resolution issues (2.2)                                     | 3.8   |
| 10/29/19 | J Bucholtz | L120 | A106     | Confer with J. Adams, W. Nordwind, P. Mathers, P. Fitzgerald, J. Bragg, and team regarding DOJ resolution issues (2.0); edit materials regarding DOJ resolution issues (1.2)  | 3.2   |
| 10/30/19 | J Bucholtz | L120 | A106     | Confer with M. Kesselman, J. Adams, W. Nordwind, P. Fitzgerald, M. Florence, P. Mathers, M. Huebner, and  | 5.5   |

08714 Purdue Pharma LP  
158001 DOJ Opioid Marketing Investigations  
12/09/19

Invoice No. 10311310  
Page 5

| Date     | Timekeeper | Task | Activity | Description   | Hours      |
|----------|------------|------|----------|---|------------|
|          |            |      |          | team regarding DOJ resolution issues (3.7); edit materials regarding DOJ resolution issues (1.8)  |            |
| 10/31/19 | J Bucholtz | L120 | A106     | Confer with M. Kesselman, P. Mathers, M. Huebner, P. Fitzgerald, J. Bragg, and team regarding DOJ resolution issues (0.6); edit materials regarding DOJ resolution issues (0.9) | 1.5        |
|          |            |      |          |   | <hr/> 64.1 |

#### TIMEKEEPER SUMMARY

| Timekeeper       | Status  | Hours      | Rate    | Value             |
|------------------|---------|------------|---------|-------------------|
| Jeffrey Bucholtz | Partner | 63.6       | 1045.00 | 66,462.00         |
| Seth Lundy       | Partner | 0.5        | 1040.00 | 520.00            |
| Total            |         | <hr/> 64.1 |         | <hr/> \$66,982.00 |

08714 Purdue Pharma LP  
158001 DOJ Opioid Marketing Investigations  
12/09/19

Invoice No. 10311310

Page 6

**Task Summary - Fees**

| <b>Task</b> |                   | <b>Hours</b> | <b>Value</b>     |
|-------------|-------------------|--------------|------------------|
| L120        | Analysis/Strategy | 64.1         | 60,283.80        |
|             | Total Fees        | <u>64.1</u>  | <u>60,283.80</u> |

# KING & SPALDING

FEDERAL I.D. 58-0520153

Remit To:  
King & Spalding LLP  
P.O. Box 116133  
Atlanta, GA 30368-6133

By Wire: SunTrust Bank  
ABA: 061 000 104  
SWIFT: SNTRUS3A  
USD Account: 88003 12475  
Account Name: King & Spalding

Purdue Pharma LP  
Sent Electronically

|              |          |
|--------------|----------|
| Invoice No.  | 10311768 |
| Invoice Date | 12/10/19 |
| Client No.   | 08714    |
| Matter No.   | 240001   |

RE: Retention And Fee Application

For questions, contact:  
Jeffrey Bucholtz (202) 626-2907

For Professional Services Rendered from October 1, 2019 through October 31, 2019:

|                              |           |                  |
|------------------------------|-----------|------------------|
| Fees                         | \$        | 104,555.00       |
| Less Agreed Discount (10.0%) |           | -10,455.50       |
| <b>Total this Invoice</b>    | <b>\$</b> | <b>94,099.50</b> |

*Payment is Due Upon Receipt*

08714 Purdue Pharma LP  
240001 Retention And Fee Application  
12/10/19

Invoice No. 10311768  
Page 2

# **PROFESSIONAL SERVICES**

| Date     | Timekeeper     | Task | Activity | Description  | Hours |
|----------|----------------|------|----------|--|-------|
| 10/03/19 | J Bucholtz     | L120 | A105     | Confer with L Shermohammed regarding retention application   | 0.2   |
| 10/03/19 | L Shermohammed | L210 | A101     | Prepare retention application in Purdue Pharma's bankruptcy proceedings  | 1.3   |
| 10/04/19 | L Shermohammed | L210 | A101     | Continue preparing retention application in Purdue Pharma's bankruptcy proceedings   | 5.6   |
| 10/07/19 | J Bucholtz     | L120 | A105     | Correspond with L. Shermohammed regarding bankruptcy application   | 0.2   |
| 10/07/19 | L Shermohammed | L210 | A104     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case (3.4); draft disclosures regarding same (2.4)  | 5.8   |
| 10/08/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case (3.6); continue to draft disclosures regarding same (2.8)  | 6.4   |
| 10/09/19 | S Borders      | L120 | A105     | Review of conflicts issues (0.2); research regarding Rule 2014 disclosures (0.3); confer with L. Shermohammed regarding same (0.1)   | 0.6   |
| 10/09/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case (1.7); continue to draft disclosures regarding same (1.2)  | 2.9   |
| 10/10/19 | S Davidson     | L110 | A104     | Review correspondence regarding retention issues (0.8); confer with L. Shermohammed regarding same (0.3)   | 1.1   |
| 10/10/19 | L Henrikson    | L120 | A101     | Conferences with L. Shermohammed and J. Jumbeck regarding conflicts (0.5); review and summarize same for 327 application (3.6)   | 4.1   |
| 10/10/19 | M Higgins      | L140 | A105     | Confer with L. Shermohammed regarding conflicts check assignment   | 0.5   |
| 10/10/19 | J Jumbeck      | L120 | A101     | Confer with L. Shermohammed regarding retention application (327(e)) disclosure requirements and outline of project (0.2); review results from conflict search detail, compared those results with list of parties-in-interest, and reported potential conflicts (4.3) | 4.5   |
| 10/10/19 | C Sae          | L250 | A104     | Review conflicts reports for 327(e) application  | 3.2   |

08714 Purdue Pharma LP  
240001 Retention And Fee Application  
12/10/19

Invoice No. 10311768  
Page 3

| Date     | Timekeeper     | Task | Activity | Description   | Hours |
|----------|----------------|------|----------|---|-------|
| 10/10/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case (5.3); continue to draft disclosures regarding same (2.6) | 7.9   |
| 10/11/19 | S Borders      | L120 | A104     | Telephone conference with J. Tucker regarding retention issues (0.1); document review regarding same (0.3)  | 0.4   |
| 10/11/19 | S Davidson     | L110 | A104     | Correspondence regarding retention issues and connection searches   | 0.8   |
| 10/11/19 | L Henrikson    | L120 | A101     | Review and summarize conflicts for 327 application  | 4.3   |
| 10/11/19 | M Higgins      | L140 | A110     | Review and document conflicts with Plaintiffs' counsel, Debtor's counsel  | 1.4   |
| 10/11/19 | J Jumbeck      | L120 | A101     | Review conflict search detail results, compared those results with parties-in-interest list (3.1); reported any potential conflicts (0.8)                 | 3.9   |
| 10/11/19 | C Sae          | L250 | A104     | Review conflicts reports for 327(e) application   | 5.6   |
| 10/11/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case (5.1); continue draft disclosures regarding same (1.1)    | 6.2   |
| 10/12/19 | M Higgins      | L140 | A110     | Review and document conflicts with Debtor's counsel, Directors and Officers' counsel, Plaintiffs  | 1.5   |
| 10/12/19 | J Jumbeck      | L120 | A101     | Review conflict search detail results, compared those results with parties-in-interest list (2.5); reported any potential conflicts (0.6)                 | 3.1   |
| 10/12/19 | C Sae          | L250 | A104     | Review conflicts reports for 327(e) application   | 3.1   |
| 10/12/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case (5.9); continue to draft disclosures regarding same (1.6) | 7.5   |
| 10/13/19 | C Sae          | L250 | A104     | Review conflicts reports for 327(e) application   | 3.8   |
| 10/13/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case and draft disclosures regarding same                      | 2.3   |
| 10/14/19 | J Bucholtz     | L120 | A105     | Correspond with L. Shermohammed, R. Jones, and team regarding bankruptcy issues   | 0.2   |

08714 Purdue Pharma LP  
240001 Retention And Fee Application  
12/10/19

Invoice No. 10311768  
Page 4

| Date     | Timekeeper     | Task | Activity | Description  | Hours |
|----------|----------------|------|----------|--|-------|
| 10/14/19 | L Henrikson    | L120 | A101     | Finalize review and summary of conflicts report for 327 application (3.9); correspond with L. Shermohammed regarding same (0.5)  | 4.4   |
| 10/14/19 | M Higgins      | L140 | A110     | Review and document conflicts with Plaintiffs  | 4.1   |
| 10/14/19 | J Jumbeck      | L120 | A101     | Review conflict search detail results and identified potential conflicts of interest regarding section 327(e) application  | 2.5   |
| 10/14/19 | C Sae          | L250 | A104     | Review conflicts reports for 327(e) application  | 0.9   |
| 10/14/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case (5.1); continue to draft disclosures regarding same (2.2)  | 7.3   |
| 10/15/19 | J Bucholtz     | L120 | A105     | Conference with S. Borders, R. Jones, L. Shermohammed and S. Davidson regarding counsel application and bankruptcy issues  | 0.4   |
| 10/15/19 | S Davidson     | L110 | A104     | Conference with J. Bucholtz, R. Jones, L. Shermohammed, and S. Borders regarding status of retention issues (0.4); review correspondence regarding connections (0.4); review correspondence regarding information for retention applications (0.3)   | 1.1   |
| 10/15/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case and draft disclosures regarding same (4.1); correspond with J. Bucholtz, S. Borders, R. Jones, and S. Davidson regarding same (1.3); correspond with D. Callier and L. Lewis regarding billing matters (0.4) | 5.8   |
| 10/16/19 | S Davidson     | L110 | A104     | Review correspondence regarding status of applications   | 0.4   |
| 10/16/19 | M Higgins      | L140 | A110     | Review and document conflicts with Taxing Authorities  | 0.7   |
| 10/16/19 | J Jumbeck      | L120 | A101     | Review conflict search detail results and identified potential conflicts of interest regarding section 327(e) application  | 3.1   |
| 10/16/19 | C Sae          | L250 | A104     | Review conflicts reports for 327(e) application  | 2.1   |
| 10/16/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all   | 7.0   |



08714 Purdue Pharma LP  
240001 Retention And Fee Application  
12/10/19

Invoice No. 10311768  
Page 5

| Date     | Timekeeper     | Task | Activity | Description  | Hours |
|----------|----------------|------|----------|--|-------|
|          |                |      |          | parties in interest to the Purdue Pharma bankruptcy case and draft disclosures regarding same (5.4); correspond with K. Martin, D. Callier, and L. Lewis regarding billing questions (0.4); revise Purdue Pharma bankruptcy case retention application (1.2) |       |
| 10/17/19 | M Higgins      | L140 | A110     | Review and document conflicts with vendors   | 0.3   |
| 10/17/19 | J Jumbeck      | L120 | A101     | Review conflict search detail results and identified potential conflicts regarding section 327(e) application disclosures and finalized results  | 0.9   |
| 10/17/19 | C Sae          | L250 | A104     | Review conflicts reports for 327(e) application and draft disclosure schedule  | 3.2   |
| 10/17/19 | L Shermohammed | L210 | A111     | Analyze conflict reports regarding all parties in interest to the Purdue Pharma bankruptcy case and draft disclosures regarding same   | 1.5   |
| 10/21/19 | L Shermohammed | L210 | A111     | Revise retention application to be filed in the Purdue Pharma bankruptcy case (2.7); analyze parties in interest to the case (1.2)   | 3.9   |
| 10/22/19 | S Borders      | L120 | A104     | Work on retention application  | 0.7   |
| 10/22/19 | L Shermohammed | L210 | A111     | Additional revisions to retention application to be filed in the Purdue Pharma bankruptcy case (1.4); analyze parties in interest to the case (1.4)  | 2.8   |
| 10/23/19 | J Bucholtz     | L120 | A105     | Telephone conferences, emails with L. Shermohammed, and team regarding bankruptcy issues (0.7); edit application (0.7);edit declaration (0.8)  | 2.2   |
| 10/23/19 | S Davidson     | L110 | A104     | Review draft of application and declaration and provide comments (0.9); correspondence regarding application/declaration, connections, etc. (0.4)  | 1.3   |
| 10/23/19 | L Shermohammed | L210 | A111     | Revise retention application to be filed in the Purdue Pharma bankruptcy case (4.1); analyze parties in interest to the case (4.3)   | 8.4   |
| 10/24/19 | J Bucholtz     | L120 | A106     | Telephone conferences, emails with S. Borders, L. Shermohammed regarding application   | 0.6   |
| 10/24/19 | S Davidson     | L110 | A104     | Review correspondence regarding draft  | 0.6   |

08714 Purdue Pharma LP  
240001 Retention And Fee Application  
12/10/19

Invoice No. 10311768  
Page 6

| Date     | Timekeeper     | Task | Activity | Description  | Hours       |
|----------|----------------|------|----------|--|-------------|
|          |                |      |          | application  |             |
| 10/24/19 | L Shermohammed | L210 | A111     | Revise retention application to be filed in the Purdue Pharma bankruptcy case (1.7); analyze parties in interest to the case (3.9) | 5.6         |
| 10/29/19 | S Davidson     | L110 | A104     | Correspondence regarding retention application and US Trustee's comments   | 0.3         |
| 10/29/19 | L Shermohammed | L210 | A111     | Review comments to Purdue Pharma bankruptcy retention application from the U.S. Trustee  | 0.4         |
| 10/30/19 | S Davidson     | L110 | A104     | Review correspondence regarding retention application and comments on same   | 0.3         |
| 10/31/19 | L Shermohammed | L210 | A111     | Revise Purdue retention application for filing   | 0.6         |
|          |                |      |          |  | <hr/> 161.8 |

#### TIMEKEEPER SUMMARY

| Timekeeper        | Status    | Hours       | Rate    | Value              |
|-------------------|-----------|-------------|---------|--------------------|
| Sarah Borders     | Partner   | 1.7         | 1135.00 | 1,929.50           |
| Jeffrey Bucholtz  | Partner   | 3.8         | 1045.00 | 3,971.00           |
| Scott Davidson    | Counsel   | 5.9         | 1130.00 | 6,667.00           |
| Lindsey Henrikson | Associate | 12.8        | 750.00  | 9,600.00           |
| Matt Higgins      | Associate | 8.5         | 450.00  | 3,825.00           |
| Jake Jumbeck      | Associate | 18.0        | 620.00  | 11,160.00          |
| Christian Sae     | Associate | 21.9        | 695.00  | 15,220.50          |
| Leia Shermohammed | Associate | 89.2        | 585.00  | 52,182.00          |
| Total             |           | <hr/> 161.8 |         | <hr/> \$104,555.00 |

08714 Purdue Pharma LP  
240001 Retention And Fee Application  
12/10/19

Invoice No. 10311768  
Page 7

**Task Summary - Fees**

| <b>Task</b>                            | <b>Hours</b> | <b>Value</b>    |
|--|--------------|-----------------|
| L110 Fact Investigation/Development    | 5.9          | 6,000.30        |
| L120 Analysis/Strategy                 | 36.3         | 23,994.45       |
| L140 Document/File Management          | 8.5          | 3,442.50        |
| L210 Pleadings                         | 89.2         | 46,963.80       |
| L250 Other Written Motions/Submissions | 21.9         | 13,698.45       |
| Total Fees                             | <hr/> 161.8  | <hr/> 94,099.50 |

# KING & SPALDING

FEDERAL I.D. 58-0520153

Remit To:  
King & Spalding LLP  
P.O. Box 116133  
Atlanta, GA 30368-6133

By Wire: SunTrust Bank  
ABA: 061 000 104  
SWIFT: SNTRUS3A  
USD Account: 88003 12475  
Account Name: King & Spalding

Purdue Pharma, LP (Document Matters)

|              |          |
|--------------|----------|
| Invoice No.  | 10310621 |
| Invoice Date | 12/06/19 |
| Client No.   | 44444    |
| Matter No.   | 190003   |

RE: DOJ/NJ/ME  
Client Matter Reference: 20190002258

For questions, contact:  
Rose Jones +1 404 215 5828

For Professional Services Rendered from 10/01/19 through 10/31/19:

|                             |           |                   |
|-----------------------------|-----------|-------------------|
| Fees                        |           | 463,906.00        |
| Less Agreed Discount (7.5%) |           | -34,792.95        |
| Fees                        | \$        | 429,113.05        |
| <b>Total this Invoice</b>   | <b>\$</b> | <b>429,113.05</b> |

*Payment is Due Upon Receipt*

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 2

12/06/19

**PROFESSIONAL SERVICES**

| <b>Date</b> | <b>Timekeeper</b> | <b>Task</b> | <b>Activity</b> | <b>Description</b>   | <b>Hours</b> |
|-------------|-------------------|-------------|-----------------|--|--------------|
| 10/01/19    | N Bass            | L140        | A110            | Coordinate, create and manage L2 privilege and pre-production work flow                                      | 8.2          |
| 10/01/19    | D Handley         | L390        | A104            | Create and circulate daily reports to project managers   | 3.4          |
| 10/01/19    | R Jones           | L120        | A110            | Prepare priority documents for production  | 4.1          |
| 10/01/19    | P Kolli           | L320        | A104            | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation       | 1.9          |
| 10/01/19    | L Maryscuk        | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 0.3          |
| 10/01/19    | J Sherman         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 0.3          |
| 10/01/19    | S Tona            | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 1.6          |
| 10/02/19    | N Bass            | L120        | A101            | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks  | 0.3          |
| 10/02/19    | N Bass            | L140        | A110            | Coordinate, create and manage L2 privilege and pre-production work flow                                      | 8.4          |
| 10/02/19    | N Bass            | L140        | A110            | Attend weekly conference call with Purdue, Skadden and Cobra regarding outstanding discovery tasks           | 0.7          |
| 10/02/19    | D Handley         | L390        | A104            | Create and circulate daily reports to project managers   | 0.8          |
| 10/02/19    | R Jones           | L120        | A110            | Participate in conference call with Purdue, TCDI and Cobra regarding outstanding discovery                   | 0.5          |
| 10/02/19    | R Jones           | L120        | A110            | Prepare priority documents for production  | 3.2          |
| 10/02/19    | R Jones           | L120        | A110            | Participate in conference call with . Hoff regarding privilege training                                      | 1.0          |
| 10/02/19    | P Kolli           | L120        | A108            | Conference call with Rob Hoff and Cobra team to discuss document review protocol                             | 1.1          |
| 10/02/19    | P Kolli           | L120        | A103            | Draft meeting notes regarding privilege  | 0.6          |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 3

12/06/19

| Date     | Timekeeper | Task | Activity | Description   | Hours |
|----------|------------|------|----------|---|-------|
|          |            |      |          | training  |       |
| 10/02/19 | S Tona     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 1.4   |
| 10/03/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow   | 2.6   |
| 10/03/19 | A Panos    | L320 | A105     | Communication with S. Patel and S. Tona regarding privilege review and proposal for modification to protocol for increased efficiency in QC review; exchange e-mails with P. Kolli regarding staffing and scheduled conference call | 0.2   |
| 10/04/19 | R Jones    | L120 | A110     | Participate in conference call with Purdue, TCDI and Cobra regarding outstanding discovery tasks  | 0.5   |
| 10/04/19 | R Jones    | L120 | A110     | Prepare priority documents for production   | 3.1   |
| 10/04/19 | K Webb     | L320 | A104     | Create L2 review workflow   | 0.6   |
| 10/07/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks   | 0.2   |
| 10/07/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow   | 7.9   |
| 10/07/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue, Skadden and Cobra regarding outstanding discovery tasks  | 0.2   |
| 10/07/19 | R Jones    | L120 | A110     | Participate in weekly call with Wiggins, Purdue, Dechert, Skadden and Cobra regarding outstanding discovery requests  | 0.3   |
| 10/07/19 | R Jones    | L120 | A110     | Prepare priority documents for production   | 5.2   |
| 10/07/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 0.9   |
| 10/07/19 | S Tona     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 2.5   |
| 10/08/19 | N Bass     | L120 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow   | 6.7   |
| 10/08/19 | N Bradley  | L320 | A104     | Quality control for privilege in connection with custodial documents  | 5.6   |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 4

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | relating to the DOJ/NJ/ME investigation  |       |
| 10/08/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.6   |
| 10/08/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 1.6   |
| 10/08/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |
| 10/08/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 4.0   |
| 10/08/19 | R Jones    | L120 | A110     | Prepare priority documents for production  | 6.2   |
| 10/08/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation       | 6.3   |
| 10/08/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |
| 10/08/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.1   |
| 10/08/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 3.5   |
| 10/08/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.0   |
| 10/08/19 | S Tona     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 2.6   |
| 10/08/19 | H Wang     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 5

12/06/19

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | investigation  |       |
| 10/09/19 | N Bass     | L140 | A101     | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks  | 0.2   |
| 10/09/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow                                      | 4.4   |
| 10/09/19 | N Bradley  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.8   |
| 10/09/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 2.4   |
| 10/09/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 5.0   |
| 10/09/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.5   |
| 10/09/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 1.8   |
| 10/09/19 | M Hervey   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 2.3   |
| 10/09/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.1   |
| 10/09/19 | R Jones    | L120 | A110     | Prepare priority documents for production  | 5.3   |
| 10/09/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation       | 2.2   |
| 10/09/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.2   |
| 10/09/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.5   |
| 10/09/19 | J Saxon    | L320 | A104     | Quality control for privilege in   | 8.0   |



44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 6

12/06/19

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | connection with custodial documents relating to the DOJ/NJ/ME investigation  |       |
| 10/09/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 2.1   |
| 10/09/19 | H Wang     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 5.5   |
| 10/10/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow  | 4.1   |
| 10/10/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 1.5   |
| 10/10/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 7.3   |
| 10/10/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 1.8   |
| 10/10/19 | R Jones    | L120 | A110     | Prepare priority documents for production  | 6.2   |
| 10/10/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                     | 4.3   |
| 10/10/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.7   |
| 10/10/19 | S Tona     | L320 | A101     | Manage quality control review for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 0.4   |
| 10/10/19 | H Wang     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 1.0   |
| 10/11/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow  | 4.9   |
| 10/11/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks                | 0.2   |
| 10/11/19 | K Brahe    | L320 | A104     | Quality control for privilege in   | 6.0   |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 7

| Date     | Timekeeper | Task | Activity | Description   | Hours |
|----------|------------|------|----------|---|-------|
|          |            |      |          | connection with custodial documents relating to the DOJ/NJ/ME investigation   |       |
| 10/11/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 6.8   |
| 10/11/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 8.0   |
| 10/11/19 | D Handley  | L190 | A111     | Communicate and coordinate with project managers, review team attorneys, and database support personnel regarding document review strategy and organization | 0.4   |
| 10/11/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers  | 1.6   |
| 10/11/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 4.5   |
| 10/11/19 | R Jones    | L120 | A110     | Prepare priority documents for production   | 7.2   |
| 10/11/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 4.2   |
| 10/11/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 8.6   |
| 10/11/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 3.0   |
| 10/11/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 7.6   |
| 10/11/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation  | 7.0   |
| 10/11/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME  | 10.0  |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 8

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | investigation  |       |
| 10/11/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 4.8   |
| 10/11/19 | J Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.5   |
| 10/11/19 | H Wang     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/12/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 2.3   |
| 10/13/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 4.8   |
| 10/13/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/14/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow                                      | 8.1   |
| 10/14/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks  | 0.3   |
| 10/14/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.0   |
| 10/14/19 | J Domozyk  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/14/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.0   |
| 10/14/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 9

12/06/19

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
| 10/14/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 1.4   |
| 10/14/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/14/19 | R Jones    | L120 | A110     | Prepare priority documents for production  | 6.1   |
| 10/14/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                     | 3.4   |
| 10/14/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 9.2   |
| 10/14/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 6.3   |
| 10/14/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/14/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 12.0  |
| 10/14/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/14/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/14/19 | N Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 1.0   |
| 10/14/19 | S Tona     | L320 | A101     | Manage quality control review for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 1.0   |
| 10/14/19 | H Wang     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME                             | 2.4   |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 10

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | investigation  |       |
| 10/15/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow                                      | 5.1   |
| 10/15/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.0   |
| 10/15/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/15/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 3.3   |
| 10/15/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.0   |
| 10/15/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 1.4   |
| 10/15/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.6   |
| 10/15/19 | R Jones    | L120 | A110     | Prepare priority documents for production  | 4.1   |
| 10/15/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.3   |
| 10/15/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.7   |
| 10/15/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 4.1   |
| 10/15/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.5  |
| 10/15/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 11

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | investigation  |       |
| 10/15/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/15/19 | N Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 7.5   |
| 10/15/19 | S Tona     | L320 | A101     | Manage quality control review for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 1.3   |
| 10/16/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue, Skadden and Cobra regarding outstanding discovery tasks                         | 0.8   |
| 10/16/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/16/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/16/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 4.5   |
| 10/16/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 10.0  |
| 10/16/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 1.1   |
| 10/16/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/16/19 | R Jones    | L120 | A110     | Participate in conference call with Purdue, Wiggin, Skadden, Dechert, and Cobra regarding outstanding discovery requests   | 1.0   |
| 10/16/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.1   |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 12

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
| 10/16/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 2.3   |
| 10/16/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/16/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.7   |
| 10/16/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/16/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/16/19 | N Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.2   |
| 10/16/19 | H Wang     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/17/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow                                      | 3.9   |
| 10/17/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.0   |
| 10/17/19 | J Domozyk  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/17/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.6   |
| 10/17/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 13

12/06/19

| <b>Date</b> | <b>Timekeeper</b> | <b>Task</b> | <b>Activity</b> | <b>Description</b>   | <b>Hours</b> |
|-------------|-------------------|-------------|-----------------|--|--------------|
| 10/17/19    | D Handley         | L390        | A104            | Create and circulate daily reports to project managers   | 1.3          |
| 10/17/19    | K Hillard         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0          |
| 10/17/19    | R Jones           | L120        | A110            | Prepare priority documents for production  | 1.1          |
| 10/17/19    | R Jones           | L120        | A110            | Analyze identified documents for privilege   | 0.4          |
| 10/17/19    | L Maryscuk        | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.0          |
| 10/17/19    | C Pak             | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0          |
| 10/17/19    | E Rankin          | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.7          |
| 10/17/19    | J Saxon           | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0          |
| 10/17/19    | R Schreck         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 3.7          |
| 10/17/19    | N Sherman         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 4.2          |
| 10/17/19    | H Wang            | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0          |
| 10/18/19    | N Bass            | L120        | A101            | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks  | 0.3          |
| 10/18/19    | N Bass            | L140        | A110            | Coordinate, create and manage L2 privilege and pre-production work flow                                      | 2.1          |
| 10/18/19    | K Brahe           | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME               | 7.0          |



44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 14

12/06/19

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | investigation  |       |
| 10/18/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/18/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.2   |
| 10/18/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 3.7   |
| 10/18/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 1.3   |
| 10/18/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/18/19 | R Jones    | L120 | A110     | Prepare priority documents for review  | 0.7   |
| 10/18/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.2   |
| 10/18/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 2.2   |
| 10/18/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 4.0   |
| 10/18/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 1.2   |
| 10/18/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/18/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.6   |
| 10/18/19 | H Wang     | L320 | A104     | Quality control for privilege in connection with custodial documents   | 8.0   |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 15

12/06/19

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | relating to the DOJ/NJ/ME investigation  |       |
| 10/19/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 1.8   |
| 10/20/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 3.0   |
| 10/21/19 | N Bass     | L120 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow                                      | 7.1   |
| 10/21/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks  | 0.3   |
| 10/21/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/21/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/21/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.0   |
| 10/21/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.1   |
| 10/21/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 1.6   |
| 10/21/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/21/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation       | 0.9   |
| 10/21/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.5   |
| 10/21/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents   | 7.0   |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 16

12/06/19

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | relating to the DOJ/NJ/ME investigation  |       |
| 10/21/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/21/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/21/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/21/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 0.6   |
| 10/21/19 | J Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 10.0  |
| 10/21/19 | N Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/21/19 | S Tona     | L320 | A101     | Manage quality control review for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 0.6   |
| 10/21/19 | H Wang     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 7.5   |
| 10/22/19 | N Bass     | L120 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow  | 8.6   |
| 10/22/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 9.2   |
| 10/22/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/22/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents   | 7.0   |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 17

12/06/19

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | relating to the DOJ/NJ/ME investigation  |       |
| 10/22/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.1   |
| 10/22/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 1.3   |
| 10/22/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/22/19 | R Jones    | L120 | A110     | Prepare priority documents for production  | 3.1   |
| 10/22/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation       | 1.1   |
| 10/22/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.9   |
| 10/22/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.9   |
| 10/22/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/22/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.6   |
| 10/22/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/22/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 5.2   |
| 10/22/19 | J Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.1   |
| 10/22/19 | N Sherman  | L320 | A104     | Quality control for privilege in   | 5.7   |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 18

12/06/19

| Date     | Timekeeper | Task | Activity | Description   | Hours |
|----------|------------|------|----------|---|-------|
|          |            |      |          | connection with custodial documents relating to the DOJ/NJ/ME investigation   |       |
| 10/22/19 | H Wang     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation            | 8.0   |
| 10/23/19 | N Bass     | L120 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow   | 6.6   |
| 10/23/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks             | 0.3   |
| 10/23/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation            | 8.8   |
| 10/23/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation            | 8.0   |
| 10/23/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation            | 6.1   |
| 10/23/19 | J Haider   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation            | 1.2   |
| 10/23/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers  | 1.2   |
| 10/23/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation            | 8.0   |
| 10/23/19 | R Jones    | L120 | A110     | Participate in conference call with Purdue, TCDI and Cobra regarding outstanding discovery tasks                        | 0.5   |
| 10/23/19 | R Jones    | L120 | A110     | Prepare priority documents for production   | 3.3   |
| 10/23/19 | R Jones    | L120 | A110     | Participate in conference call with Purdue, Skadden, Wiggin, Dechert and Cobra regarding outstanding discovery requests | 1.0   |
| 10/23/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                  | 1.5   |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 19

12/06/19

| <b>Date</b> | <b>Timekeeper</b> | <b>Task</b> | <b>Activity</b> | <b>Description</b>   | <b>Hours</b> |
|-------------|-------------------|-------------|-----------------|--|--------------|
| 10/23/19    | L Maryscuk        | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 7.7          |
| 10/23/19    | L McGovern        | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 3.7          |
| 10/23/19    | C Pak             | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0          |
| 10/23/19    | E Rankin          | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 9.0          |
| 10/23/19    | J Saxon           | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0          |
| 10/23/19    | R Schreck         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 6.4          |
| 10/23/19    | J Sherman         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.6          |
| 10/23/19    | N Sherman         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 6.0          |
| 10/23/19    | S Tona            | L320        | A101            | Manage quality control review for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 0.6          |
| 10/23/19    | H Wang            | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 6.0          |
| 10/24/19    | N Bass            | L120        | A110            | Coordinate, create and manage L2 privilege and pre-production work flow  | 7.7          |
| 10/24/19    | K Brahe           | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0          |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 20

12/06/19

| <b>Date</b> | <b>Timekeeper</b> | <b>Task</b> | <b>Activity</b> | <b>Description</b>   | <b>Hours</b> |
|-------------|-------------------|-------------|-----------------|--|--------------|
| 10/24/19    | J Domozyck        | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0          |
| 10/24/19    | A Grady           | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 1.0          |
| 10/24/19    | D Handley         | L390        | A104            | Create and circulate daily reports to project managers   | 0.9          |
| 10/24/19    | K Hillard         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0          |
| 10/24/19    | R Jones           | L120        | A110            | Prepare priority documents for production  | 4.7          |
| 10/24/19    | P Kolli           | L320        | A104            | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation       | 3.1          |
| 10/24/19    | L Maryscuk        | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.1          |
| 10/24/19    | L McGovern        | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.0          |
| 10/24/19    | C Pak             | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.1          |
| 10/24/19    | E Rankin          | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 12.0         |
| 10/24/19    | J Saxon           | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0          |
| 10/24/19    | R Schreck         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.6          |
| 10/24/19    | J Sherman         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME               | 9.0          |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 21

| Date     | Timekeeper | Task | Activity | Description   | Hours |
|----------|------------|------|----------|---|-------|
| 10/24/19 | N Sherman  | L320 | A104     | investigation<br>Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.5   |
| 10/25/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks                   | 0.2   |
| 10/25/19 | N Bass     | L120 | A101     | Teleconference with Purdue Pharma, Wiggin and Cobra regarding productions   | 0.4   |
| 10/25/19 | N Bass     | L120 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow   | 7.2   |
| 10/25/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                  | 6.0   |
| 10/25/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                  | 8.0   |
| 10/25/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                  | 6.1   |
| 10/25/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers  | 1.1   |
| 10/25/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                  | 8.0   |
| 10/25/19 | R Jones    | L120 | A110     | Participate in conference call with Purdue, TCDI and Cobra regarding outstanding obligations                                  | 0.5   |
| 10/25/19 | R Jones    | L120 | A110     | Prepare priority documents for production   | 4.2   |
| 10/25/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                        | 1.2   |
| 10/25/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                  | 7.8   |
| 10/25/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME                                | 2.1   |



44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 22

12/06/19

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | investigation  |       |
| 10/25/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/25/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 2.4   |
| 10/25/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/25/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/25/19 | J Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 3.3   |
| 10/25/19 | N Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/25/19 | S Tona     | L320 | A101     | Manage quality control review for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 2.8   |
| 10/26/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 2.8   |
| 10/26/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 2.7   |
| 10/26/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 0.9   |
| 10/28/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks                | 0.2   |
| 10/28/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue, Skadden and Cobra regarding   | 1.2   |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 23

12/06/19

| Date     | Timekeeper | Task | Activity | Description   | Hours |
|----------|------------|------|----------|---|-------|
|          |            |      |          | outstanding discovery tasks   |       |
| 10/28/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow   | 7.9   |
| 10/28/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation        | 10.0  |
| 10/28/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation        | 10.0  |
| 10/28/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation        | 4.3   |
| 10/28/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers  | 0.9   |
| 10/28/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation        | 8.0   |
| 10/28/19 | R Jones    | L120 | A110     | Participate in conference call with Purdue, TCDI and Cobra regarding outstanding discovery tasks                    | 0.5   |
| 10/28/19 | R Jones    | L120 | A110     | Participate in weekly call with Purdue, Wiggin, Skadden, Dechert and Cobra regarding outstanding discovery requests | 1.2   |
| 10/28/19 | R Jones    | L120 | A110     | Prepare priority documents for production   | 7.1   |
| 10/28/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation              | 8.0   |
| 10/28/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation        | 8.0   |
| 10/28/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation        | 8.0   |
| 10/28/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation        | 10.0  |
| 10/28/19 | E Rankin   | L320 | A104     | Quality control for privilege in  | 11.0  |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 24

12/06/19

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
|          |            |      |          | connection with custodial documents relating to the DOJ/NJ/ME investigation                                  |       |
| 10/28/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/28/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/28/19 | J Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |
| 10/28/19 | N Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.2   |
| 10/29/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow                                      | 7.8   |
| 10/29/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |
| 10/29/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.5   |
| 10/29/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 4.5   |
| 10/29/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 0.8   |
| 10/29/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |
| 10/29/19 | R Jones    | L120 | A110     | Participate in conference call with Wiggin and Cobra regarding production requests                           | 0.7   |
| 10/29/19 | R Jones    | L120 | A110     | Prepare priority documents for production  | 4.9   |
| 10/29/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the                               | 4.4   |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 25

| Date     | Timekeeper | Task | Activity | Description   | Hours |
|----------|------------|------|----------|---|-------|
| 10/29/19 | L Maryscuk | L320 | A104     | DOJ/NJ/ME investigation<br>Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.1   |
| 10/29/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                            | 10.6  |
| 10/29/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                            | 10.0  |
| 10/29/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                            | 9.0   |
| 10/29/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                            | 10.0  |
| 10/29/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                            | 8.4   |
| 10/29/19 | J Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                            | 10.4  |
| 10/29/19 | N Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                            | 8.3   |
| 10/29/19 | E Smedley  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                            | 4.5   |
| 10/29/19 | S Tona     | L320 | A101     | Manage quality control review for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation              | 0.8   |
| 10/30/19 | N Bass     | L120 | A101     | Attend weekly conference call with Purdue Pharma L.P., Cobra and TCDI regarding outstanding discovery tasks                             | 0.3   |
| 10/30/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow   | 8.2   |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 26

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
| 10/30/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |
| 10/30/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |
| 10/30/19 | M Douglas  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.0   |
| 10/30/19 | M Dyer     | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.1   |
| 10/30/19 | A Grady    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.0   |
| 10/30/19 | D Handley  | L390 | A104     | Create and circulate daily reports to project managers   | 0.9   |
| 10/30/19 | K Hillard  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |
| 10/30/19 | R Jones    | L120 | A110     | Prepare priority documents for production  | 1.9   |
| 10/30/19 | R Jones    | L120 | A110     | Participate in conference call with TCDI and Cobra regarding outstanding production requests                 | 0.2   |
| 10/30/19 | P Kolli    | L320 | A104     | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation       | 6.7   |
| 10/30/19 | L Maryscuk | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0  |
| 10/30/19 | L McGovern | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 7.0   |
| 10/30/19 | C Pak      | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.3   |

44444 Purdue Pharma, LP (Document Matters)  
 190003 DOJ/NJ/ME  
 12/06/19

Invoice No. 10310621

Page 27

| Date     | Timekeeper | Task | Activity | Description  | Hours |
|----------|------------|------|----------|--|-------|
| 10/30/19 | E Rankin   | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 9.0   |
| 10/30/19 | J Saxon    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 10.0  |
| 10/30/19 | R Schreck  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/30/19 | J Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 9.6   |
| 10/30/19 | N Sherman  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.3   |
| 10/30/19 | E Smedley  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.0   |
| 10/30/19 | S Tona     | L320 | A101     | Manage quality control review for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 0.8   |
| 10/31/19 | N Bass     | L140 | A110     | Coordinate, create and manage L2 privilege and pre-production work flow  | 7.7   |
| 10/31/19 | K Brahe    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 10.0  |
| 10/31/19 | J Domozick | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 10.0  |
| 10/31/19 | M Douglas  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 9.0   |
| 10/31/19 | F Evans    | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation               | 8.1   |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 28

12/06/19

| <b>Date</b> | <b>Timekeeper</b> | <b>Task</b> | <b>Activity</b> | <b>Description</b>   | <b>Hours</b> |
|-------------|-------------------|-------------|-----------------|--|--------------|
| 10/31/19    | A Grady           | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 6.1          |
| 10/31/19    | D Handley         | L390        | A104            | Create and circulate daily reports to project managers   | 1.1          |
| 10/31/19    | K Hillard         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0         |
| 10/31/19    | R Jones           | L120        | A110            | Prepare priority documents for production  | 3.4          |
| 10/31/19    | P Kolli           | L320        | A104            | Manage QC for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation       | 4.0          |
| 10/31/19    | L Maryscuk        | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0         |
| 10/31/19    | L McGovern        | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.9         |
| 10/31/19    | C Pak             | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 9.8          |
| 10/31/19    | A Panos           | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 2.9          |
| 10/31/19    | E Rankin          | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 10.0         |
| 10/31/19    | J Saxon           | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 11.0         |
| 10/31/19    | R Schreck         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.1          |
| 10/31/19    | J Sherman         | L320        | A104            | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME               | 8.2          |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 29

12/06/19

| Date     | Timekeeper | Task | Activity | Description   | Hours        |
|----------|------------|------|----------|---|--------------|
| 10/31/19 | N Sherman  | L320 | A104     | investigation<br>Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation | 8.1          |
| 10/31/19 | E Smedley  | L320 | A104     | Quality control for privilege in connection with custodial documents relating to the DOJ/NJ/ME investigation                  | 10.0         |
|          |            |      |          |   | <hr/> 1994.0 |



44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 30

12/06/19

**TIMEKEEPER SUMMARY**

| <b>Timekeeper</b> | <b>Status</b>             | <b>Hours</b> | <b>Rate</b> | <b>Value</b> |
|-------------------|---------------------------|--------------|-------------|--------------|
| Rose Jones        | Partner                   | 93.4         | 425.00      | 39,695.00    |
| Nicole Bass       | Discovery Counsel         | 141.3        | 325.00      | 45,922.50    |
| Michael Douglas   | Privilege Review Attorney | 16.0         | 215.00      | 3,440.00     |
| Frankie Evans     | Privilege Review Attorney | 8.1          | 215.00      | 1,741.50     |
| Antoine Grady     | Privilege Review Attorney | 98.4         | 215.00      | 21,156.00    |
| Jay Haider        | Privilege Review Attorney | 92.9         | 215.00      | 19,973.50    |
| Priya Kolli       | Privilege Review Attorney | 55.8         | 215.00      | 11,997.00    |
| Lori Maryscuk     | Privilege Review Attorney | 161.0        | 215.00      | 34,615.00    |
| Liz McGovern      | Privilege Review Attorney | 85.7         | 215.00      | 18,425.50    |
| Chong Pak         | Privilege Review Attorney | 144.7        | 215.00      | 31,110.50    |
| Alex Panos        | Privilege Review Attorney | 3.1          | 215.00      | 666.50       |
| Reilly Schreck    | Privilege Review Attorney | 107.5        | 215.00      | 23,112.50    |
| Eric Smedley      | Privilege Review Attorney | 22.5         | 215.00      | 4,837.50     |
| Sarah Tona        | Privilege Review Attorney | 16.4         | 215.00      | 3,526.00     |
| Katherine Webb    | Discovery Counsel         | 0.6          | 280.00      | 168.00       |
| Nikki Bradley     | Privilege Review Attorney | 12.4         | 215.00      | 2,666.00     |
| Kyle Brahe        | Privilege Review Attorney | 136.0        | 215.00      | 29,240.00    |
| Jeffrey Domozyk   | Privilege Review Attorney | 119.5        | 215.00      | 25,692.50    |
| Matthew Dyer      | Privilege Review Attorney | 8.1          | 215.00      | 1,741.50     |
| Michael Hervey    | Privilege Review Attorney | 2.3          | 215.00      | 494.50       |
| Kimberlee Hillard | Privilege Review Attorney | 131.2        | 215.00      | 28,208.00    |
| Elizabeth Rankin  | Privilege Review Attorney | 126.1        | 215.00      | 27,111.50    |
| Justin Saxon      | Privilege Review Attorney | 140.5        | 215.00      | 30,207.50    |
| Nathaniel Sherman | Privilege Review Attorney | 89.0         | 215.00      | 19,135.00    |
| Joseph Sherman    | Privilege Review Attorney | 85.0         | 215.00      | 18,275.00    |
| Hao Wang          | Privilege Review Attorney | 70.4         | 215.00      | 15,136.00    |
| Dan Handley       | Paralegal                 | 26.1         | 215.00      | 5,611.50     |
| Total             |                           | 1994.0       |             | \$463,906.00 |

44444 Purdue Pharma, LP (Document Matters)

Invoice No. 10310621

190003 DOJ/NJ/ME

Page 31

12/06/19

**Task Summary - Fees**

| <b>Task</b> |                               | <b>Hours</b>  | <b>Value</b>      |
|-------------|-------------------------------|---------------|-------------------|
| L120        | Analysis/Strategy             | 144.2         | 51,816.58         |
| L140        | Document/File Management      | 92.2          | 27,717.95         |
| L190        | Other Case Assessment         | 0.4           | 79.55             |
| L320        | Document Production (Defense) | 1731.5        | 344,387.90        |
| L390        | Other Discovery (Defense)     | 25.7          | 5,111.07          |
|             | Total Fees                    | <u>1994.0</u> | <u>429,113.05</u> |